U2AF1 and myelodysplastic syndrome: Approximately 50% of MDS patients have a mutation in SF3B1, U2AF1, SRSF2, or ZRSR2 (Yoshida et al. 2011; Haferlach et al. 2014; Nguyen et al. 2018).